"The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.
Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has retu"...
There is no known antidote for overdoses with Jakafi. Single doses up to 200 mg have been given with acceptable acute tolerability. Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anemia and thrombocytopenia. Appropriate supportive treatment should be given.
Hemodialysis is not expected to enhance the elimination of ruxolitinib.
Last reviewed on RxList: 8/8/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Jakafi Information
Report Problems to the Food and Drug Administration
Find out what women really need.